Results 161 to 170 of about 4,025 (198)
Some of the next articles are maybe not open access.
Fidaxomicin: Balancing evidence and economics
American Journal of Health-System Pharmacy, 2012Over the past 10 years, Clostridium difficile infection (CDI) has become a leading cause of nosocomial infection and a significant source of health care expenditures in the United States. The standard therapies for CDI—oral vancomycin and metronidazole—are both associated with significant ...
Vanessa, Stevens +2 more
openaire +2 more sources
Probable fidaxomicin-induced pancytopenia
American Journal of Health-System Pharmacy, 2018A case of pancytopenia in a patient receiving treatment with fidaxomicin for Clostridium difficile infection (CDI) is described.A 33-year-old Caucasian woman was admitted to the hospital with a chief complaint of loose stools occurring approximately 7 times a day; she also reported fever, nausea, diffuse abdominal pain, and fatigue.
Samantha, Axtell +2 more
openaire +2 more sources
Clarifications about add-on payments for fidaxomicin
American Journal of Health-System Pharmacy, 2013The efforts of AJHP, through a news article,[1][1] to educate a pharmacy audience about the new technology add-on payment (NTAP) for fidaxomicin tablets are to be commended. We wish to provide clarification and update readers about recent developments.
Hemal, Shah +2 more
openaire +2 more sources
Fidaxomicin for the Treatment of Clostridium diffìcile Infections
Annals of Pharmacotherapy, 2012Objective: To evaluate the pharmacology, microbiology, safety, and efficacy of fidaxomicin for treatment of Clostridium difficile infections (CDI). Data Sources: Literature was identified through Ovid MEDLINE (1940-December 2011) and ...
Craig B, Whitman, Quinn A, Czosnowski
openaire +2 more sources
Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
Clinical Microbiology and Infection, 2021Joel Hay +2 more
exaly